Zacks: Brokerages Expect Cardlytics Inc (NASDAQ:CDLX) Will Post Quarterly Sales of $69.32 Million

Analysts predict that Cardlytics Inc (NASDAQ:CDLX) will post sales of $69.32 million for the current quarter, Zacks reports. Three analysts have made estimates for Cardlytics’ earnings. The highest sales estimate is $69.46 million and the lowest is $69.10 million. Cardlytics posted sales of $47.82 million during the same quarter last year, which suggests a positive year-over-year growth rate of 45%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 3rd.

According to Zacks, analysts expect that Cardlytics will report full year sales of $206.37 million for the current year, with estimates ranging from $200.00 million to $210.60 million. For the next year, analysts forecast that the firm will report sales of $277.26 million, with estimates ranging from $265.10 million to $288.24 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.31. The company had revenue of $56.42 million for the quarter, compared to the consensus estimate of $50.02 million. Cardlytics had a negative return on equity of 44.53% and a negative net margin of 17.01%. The firm’s revenue was up 63.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.15) EPS.

A number of research analysts have recently issued reports on the company. Zacks Investment Research raised Cardlytics from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research note on Thursday, January 16th. Raymond James downgraded Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They noted that the move was a valuation call. JPMorgan Chase & Co. downgraded Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price target on the stock. in a research note on Thursday, November 14th. They noted that the move was a valuation call. Craig Hallum upped their price target on Cardlytics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. Finally, Bank of America reaffirmed an “average” rating and set a $100.00 price target on shares of Cardlytics in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $66.43.

In other news, COO Lynne Marie Laube sold 5,740 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.86, for a total value of $498,576.40. Following the completion of the transaction, the chief operating officer now directly owns 340,567 shares of the company’s stock, valued at $29,581,649.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Scott D. Grimes sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $61.11, for a total value of $61,110.00. Following the completion of the transaction, the chief executive officer now directly owns 406,750 shares of the company’s stock, valued at $24,856,492.50. The disclosure for this sale can be found here. Insiders have sold a total of 446,766 shares of company stock valued at $26,586,644 over the last three months. Corporate insiders own 21.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in CDLX. Bank of Montreal Can grew its holdings in Cardlytics by 16,371.4% during the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Cardlytics during the fourth quarter valued at $88,000. Tower Research Capital LLC TRC grew its holdings in Cardlytics by 35.0% during the third quarter. Tower Research Capital LLC TRC now owns 4,079 shares of the company’s stock valued at $137,000 after purchasing an additional 1,057 shares during the period. Metropolitan Life Insurance Co NY bought a new position in Cardlytics during the third quarter valued at $161,000. Finally, Capital Investment Advisors LLC bought a new position in Cardlytics during the third quarter valued at $253,000. 93.41% of the stock is owned by institutional investors.

Shares of NASDAQ:CDLX traded up $1.26 during midday trading on Monday, reaching $87.33. The company’s stock had a trading volume of 269,800 shares, compared to its average volume of 553,289. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -60.71 and a beta of 1.72. The firm has a 50 day moving average price of $66.71 and a two-hundred day moving average price of $44.65. Cardlytics has a fifty-two week low of $14.14 and a fifty-two week high of $90.50.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What is required to own or exchange cryptocurrency?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.